Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...

Q4 2025 Management View CEO Barry Port opened by emphasizing "another record year and record quarter in several key areas," highlighting the clinical outcomes achieved by the company's care teams and ...